TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses

Vaccine

Volumn 31, Issue 49, 2013, Pages 5848-5855

  Fox, Christopher B ^a   Moutaftsi, Magdalini ^a   Vergara, Julie ^a   Desbien, Anthony L ^a   Nana, Ghislain I ^a   Vedvick, Thomas S ^a   Coler, Rhea N ^a   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Aqueous nanosuspension; Glucopyranosyl lipid adjuvant; Liposome; Oil in water emulsion; Th1 type immunity; Vaccine adjuvant formulation

Indexed keywords

ADJUVANT; BREFELDIN A; CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; GLUCOPYRANOSYL LIPID ADJUVANT; IMMUNOLOGICAL ADJUVANT; LIPID; LIPOSOME; RECOMBINANT ANTIGEN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; AQUEOUS SOLUTION; ARTICLE; BIOCHEMICAL COMPOSITION; BIOLOGICAL ACTIVITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; MALARIA; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMODIUM BERGHEI; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SPLEEN CELL; ZETA POTENTIAL;

AQUEOUS NANOSUSPENSION; GLUCOPYRANOSYL LIPID ADJUVANT; LIPOSOME; OIL-IN-WATER EMULSION; TH1-TYPE IMMUNITY; VACCINE ADJUVANT FORMULATION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; LIGANDS; MALARIA VACCINES; MICE; MICE, INBRED C57BL; PLASMODIUM BERGHEI; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SUBUNIT;

EID: 84887607771     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.069     Document Type: Article

References (31)

1. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003, 2(9):727-735.
2. Morel S., Diderlaurent A., Bourguignon P., Delhaye S., Baras B., Jacob V., et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
3. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Nat Acad Sci USA 2008, 105:10501-10506.
4. Mettens P., Dubois P.M., Demoitie M.A., Bayat B., Donner M.N., Bourguignon P., et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 2008, 26(8):1072-1082.
5. Owusu-Agyei S., Ansong D., Asante K., Owusu S.K., Owusu R., Brobby N.A.W., et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE 2009, 4:e7302.
6. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200(3):337-346.
7. Polhemus M.E., Remich S.A., Ogutu B.R., Waitumbi J.N., Otieno L., Apollo S., et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One 2009, 4(7):e6465.
8. Stewart V.A., McGrath S.M., Walsh D.S., Davis S., Hess A.S., Ware L.A., et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 2006, 24(42-43):6483-6492.
9. Ansong D., Asante K.P., Vekemans J., Owusu S.K., Owusu R., Brobby N.A.W., et al. Responses to the RTS,S/AS01E and RTS,S/AS02D malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS ONE 2011, 6:18891.
10. Coler R.N., Baldwin S.L., Shaverdian N., Bertholet S., Reed S.J., Raman V.S., et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 2010, 5:e13677.
11. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Plessner Windish H., Baldwin S.L. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 2011, 6:e16333.
12. Anderson R.C., Fox C.B., Dutill T.S., Shaverdian N., Evers T.L., Poshusta G.R., et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Coll Surf B 2010, 75:123-132.
13. Fox C.B., Baldwin S.L., Duthie M.S., Reed S.G., Vedvick T.S. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 2011, 29:9563-9572.
14. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47.
15. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27:5956-5963.
16. Allison A.C., Eugui E.M. The role of cell-mediated immune responses in resistance to malaria, with special reference to oxidant stress. Annu Rev Immunol 1983, 1:361-392.
17. Orr M.T., Fox C.B., Baldwin S.L., Sivananthan S.J., Lucas E., Lin S., et al. Adjuvant formulation structure and composition is critical for the development of an effective vaccine against tuberculosis. J Control Release 2013, 172(1):190-200.
18. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
19. Fox C.B., Anderson R.C., Dutill T.S., Goto Y., Reed S.G., Vedvick T. Monitoring the effects of component structure and source and formulation stability and adjuvant activity of oil-in-water emulsions. Coll Surf B 2008, 65:98-105.
20. Misquith A., Fung H.W.M., Dowling Q.M., Guderian J.A., Vedvick T.S., Fox C.B. In vitro evaluation of TLR4 agonist activity: formulation effects. Coll Surf B 2014, 113:312-319.
21. Waite D.C., Jacobson E.W., Ennis F.A., Edelman R., White B., Kammer R., et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001, 19:3957-3967.
22. Fox C.B. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 2009, 14:3286-3312.
23. Schmitz N., Beerli R.R., Bauer M., Jegerlehner A., Dietmeier K., Maudrich M., et al. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 2012, 42:863-869.
24. Baudner B.C., Ronconi V., Casini D., Tortoli M., Kazzaz J., Singh M., et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res 2009, 26:1477-1485.
25. Falo L.D., Kovacsovics-Bankowski M., Thompson K., Rock K.L. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1995, 1:649-653.
26. Kovacsovics-Bankowski M., Rock K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995, 267:243-246.
27. Sun P., Schwenk R., White K., Stoute J.A., Cohen J., Ballou W.R., et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ. J Immunol 2003, 171:6961-6967.
28. Fox C.B., Baldwin S.L., Vedvick T.S., Angov E., Reed S.G. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clin Vaccine Immunol 2012, 19:1633-1640.
29. Gao N., Dang T., Yuan D. IFN-γ-dependent and -independent initiation of switch recombination by NK cells. J Immunol 2001, 167:2011-2018.
30. Markine-Goriaynoff D., van der Logt J.T.M., Truyens C., Nguyen T.D., Heessen F.W.A., Bigaignon G., et al. IFN-γ-independent IgG2a production in mice infected with viruses and parasites. Int Immunol 2000, 12:223-230.
31. Bergmann-Leitner E., Hosie H., Trichilo J., DeRiso E., Ranallo R.T., Alefantis T., et al. Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria. Frontiers Immunol 2013, 4:176.